Growth of asthmatic children during treatment with budesonide: a double blind trial.
OBJECTIVE
To determine whether the inhaled glucocorticosteroid budesonide has any adverse effect on short term linear growth in children with mild asthma.


METHODS
Outpatient clinic in secondary referral centre.


METHODS
15 children aged 6-13 years with normal statural growth velocity during the previous year, no signs of puberty, and no use of systemic or topical steroids in the two months before the study. DESIGN OF INTERVENTIONS: Double blind, randomised crossover trial with two active periods in which budesonide was given in divided daily doses of 200 micrograms and 800 micrograms. During run in and two washout periods placebo was given. After the second washout period the children received open treatment with 400 micrograms budesonide daily. All periods were of 18 days' duration.


METHODS
Growth of the lower leg as measured twice a week by knemometry.


RESULTS
Mean growth velocity of the lower leg was 0.63 mm/week during run in and during washout 0.64 mm/week. Budesonide treatment was associated with a significant dose related reduction of growth velocity: the mean reduction in growth velocity during treatment was 0.11 (95% confidence interval -0.15 0.36 (0.13 to 0.59) mm/week with 800 micrograms budesonide (p less than 0.05; Page's test). During treatment with 400 micrograms budesonide a reduction of 0.17 (-0.10 to 0.45) mm/week was found.


CONCLUSIONS
Treatment with inhaled budesonide is associated with a dose related suppression of short term linear growth in children with mild asthma.
Wolthers
O D
OD
Department of Paediatrics, Kolding Hospital, Denmark.
Pedersen
S
S
D000293:Adolescent; D000886:Anthropometry; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000009:adverse effects*; D019819:Budesonide; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007866:Leg / Q000254:growth & development; D008297:Male; D010366:Peak Expiratory Flow Rate; D011282:Pregnenediones / Q000009:adverse effects*
D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide